Vol. 4 No. 2 (2024): February
Reimbursement Reviews

Ibrutinib (Imbruvica)

decorative image of the issue cover

Published February 9, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ibrutinib (Imbruvica) 140 mg capsule, oral.
  • Indication: Ibrutinib in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, including those with 17p deletion.